Skip to content
Screener

EBITDA at other companies

Eli Lilly logo
Eli LillyLLY
$9.78B+34.8%
Amgen logo
AmgenAMGN
$4.63B+15.7%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-$45.65M-6.9%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$91.95M-99.5%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$122.6M-31.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$3.19B+719%
Enterprise value$3.15B+798%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Calculated from MBX Biosciences, Inc.’s reported figures.

$27.3Mebit+
$64.0KDepreciation Depletion & Amortization
=-$27.2M

The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 9:03 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210593

FAQ

What is MBX Biosciences, Inc.'s EBITDA?
MBX Biosciences, Inc. (MBX) reported EBITDA of -$27.2M in Q1 2026.
How has MBX Biosciences, Inc.'s EBITDA changed year-over-year?
MBX Biosciences, Inc.'s EBITDA decreased by 2.8% year-over-year, from -$26.45M to -$27.2M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about MBX Biosciences, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude